Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-trace').style.display = (document.getElementById('cakeErr67f09e0d17bd7-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f09e0d17bd7-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-code').style.display = (document.getElementById('cakeErr67f09e0d17bd7-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-context').style.display = (document.getElementById('cakeErr67f09e0d17bd7-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f09e0d17bd7-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f09e0d17bd7-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 15697,
		&#039;title&#039; =&gt; &#039;More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times&lt;br /&gt;
&lt;br /&gt;
A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;
&lt;br /&gt;
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;
&lt;br /&gt;
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;
&lt;br /&gt;
Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;
&lt;br /&gt;
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;
&lt;br /&gt;
A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;
&lt;br /&gt;
Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;
&lt;br /&gt;
However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;
&lt;br /&gt;
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;
&lt;br /&gt;
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15824,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 15697,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times

A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;br /&gt;&lt;br /&gt;A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;&lt;br /&gt;Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;&lt;br /&gt;Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;&lt;br /&gt;Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;&lt;br /&gt;According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;&lt;br /&gt;A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;&lt;br /&gt;Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;&lt;br /&gt;However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;&lt;br /&gt;India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;&lt;br /&gt;&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;&lt;br /&gt;New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;&lt;br /&gt;In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;&lt;br /&gt;&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 15697,
	&#039;title&#039; =&gt; &#039;More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times&lt;br /&gt;
&lt;br /&gt;
A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;
&lt;br /&gt;
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;
&lt;br /&gt;
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;
&lt;br /&gt;
Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;
&lt;br /&gt;
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;
&lt;br /&gt;
A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;
&lt;br /&gt;
Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;
&lt;br /&gt;
However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;
&lt;br /&gt;
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;
&lt;br /&gt;
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15824,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 15697
$metaTitle = &#039;LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;
$metaKeywords = &#039;patents,medicines,Health&#039;
$metaDesc = &#039;
-The Economic Times

A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;br /&gt;&lt;br /&gt;A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;&lt;br /&gt;Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;&lt;br /&gt;Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;&lt;br /&gt;Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;&lt;br /&gt;According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;&lt;br /&gt;A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;&lt;br /&gt;Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;&lt;br /&gt;However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;&lt;br /&gt;India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;&lt;br /&gt;&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;&lt;br /&gt;New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;&lt;br /&gt;In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;&lt;br /&gt;&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh | Im4change.org</title>
    <meta name="description" content="
-The Economic Times

A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Economic Times<br /><br />A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br /><br />Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br /><br />Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br /><br />Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br /><br />According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br /><br />In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br /><br />A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br /><br />Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br /><br />However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br /><br />India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br /><br />&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br /><br />Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br /><br />New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br /><br />In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br /><br />&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-trace').style.display = (document.getElementById('cakeErr67f09e0d17bd7-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f09e0d17bd7-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-code').style.display = (document.getElementById('cakeErr67f09e0d17bd7-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-context').style.display = (document.getElementById('cakeErr67f09e0d17bd7-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f09e0d17bd7-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f09e0d17bd7-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 15697,
		&#039;title&#039; =&gt; &#039;More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times&lt;br /&gt;
&lt;br /&gt;
A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;
&lt;br /&gt;
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;
&lt;br /&gt;
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;
&lt;br /&gt;
Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;
&lt;br /&gt;
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;
&lt;br /&gt;
A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;
&lt;br /&gt;
Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;
&lt;br /&gt;
However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;
&lt;br /&gt;
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;
&lt;br /&gt;
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15824,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 15697,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times

A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;br /&gt;&lt;br /&gt;A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;&lt;br /&gt;Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;&lt;br /&gt;Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;&lt;br /&gt;Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;&lt;br /&gt;According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;&lt;br /&gt;A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;&lt;br /&gt;Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;&lt;br /&gt;However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;&lt;br /&gt;India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;&lt;br /&gt;&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;&lt;br /&gt;New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;&lt;br /&gt;In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;&lt;br /&gt;&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 15697,
	&#039;title&#039; =&gt; &#039;More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times&lt;br /&gt;
&lt;br /&gt;
A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;
&lt;br /&gt;
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;
&lt;br /&gt;
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;
&lt;br /&gt;
Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;
&lt;br /&gt;
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;
&lt;br /&gt;
A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;
&lt;br /&gt;
Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;
&lt;br /&gt;
However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;
&lt;br /&gt;
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;
&lt;br /&gt;
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15824,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 15697
$metaTitle = &#039;LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;
$metaKeywords = &#039;patents,medicines,Health&#039;
$metaDesc = &#039;
-The Economic Times

A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;br /&gt;&lt;br /&gt;A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;&lt;br /&gt;Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;&lt;br /&gt;Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;&lt;br /&gt;Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;&lt;br /&gt;According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;&lt;br /&gt;A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;&lt;br /&gt;Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;&lt;br /&gt;However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;&lt;br /&gt;India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;&lt;br /&gt;&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;&lt;br /&gt;New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;&lt;br /&gt;In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;&lt;br /&gt;&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh | Im4change.org</title>
    <meta name="description" content="
-The Economic Times

A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Economic Times<br /><br />A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br /><br />Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br /><br />Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br /><br />Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br /><br />According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br /><br />In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br /><br />A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br /><br />Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br /><br />However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br /><br />India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br /><br />&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br /><br />Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br /><br />New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br /><br />In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br /><br />&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-trace').style.display = (document.getElementById('cakeErr67f09e0d17bd7-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f09e0d17bd7-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-code').style.display = (document.getElementById('cakeErr67f09e0d17bd7-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f09e0d17bd7-context').style.display = (document.getElementById('cakeErr67f09e0d17bd7-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f09e0d17bd7-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f09e0d17bd7-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 15697,
		&#039;title&#039; =&gt; &#039;More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times&lt;br /&gt;
&lt;br /&gt;
A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;
&lt;br /&gt;
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;
&lt;br /&gt;
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;
&lt;br /&gt;
Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;
&lt;br /&gt;
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;
&lt;br /&gt;
A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;
&lt;br /&gt;
Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;
&lt;br /&gt;
However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;
&lt;br /&gt;
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;
&lt;br /&gt;
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15824,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 15697,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times

A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;br /&gt;&lt;br /&gt;A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;&lt;br /&gt;Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;&lt;br /&gt;Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;&lt;br /&gt;Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;&lt;br /&gt;According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;&lt;br /&gt;A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;&lt;br /&gt;Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;&lt;br /&gt;However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;&lt;br /&gt;India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;&lt;br /&gt;&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;&lt;br /&gt;New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;&lt;br /&gt;In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;&lt;br /&gt;&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 15697,
	&#039;title&#039; =&gt; &#039;More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Economic Times&lt;br /&gt;
&lt;br /&gt;
A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;
&lt;br /&gt;
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;
&lt;br /&gt;
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;
&lt;br /&gt;
Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;
&lt;br /&gt;
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;
&lt;br /&gt;
A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;
&lt;br /&gt;
Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;
&lt;br /&gt;
However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;
&lt;br /&gt;
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;
&lt;br /&gt;
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;
&lt;br /&gt;
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15824,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 15697
$metaTitle = &#039;LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh&#039;
$metaKeywords = &#039;patents,medicines,Health&#039;
$metaDesc = &#039;
-The Economic Times

A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Economic Times&lt;br /&gt;&lt;br /&gt;A growing number of countries are adopting India&#039;s intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.&lt;br /&gt;&lt;br /&gt;Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.&lt;br /&gt;&lt;br /&gt;Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.&lt;br /&gt;&lt;br /&gt;Experts say IP laws were earlier framed in the West and adopted by developing countries. &amp;quot;Strangely, India is now setting the IP laws for developing countries,&amp;quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.&lt;br /&gt;&lt;br /&gt;According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India&#039;s decision to grant compulsory licence to Natco Pharma. &amp;quot;It was a question of who will bell the cat,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;In March, India issued the country&#039;s first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG&#039;s patented cancer drug, Nexavar, at 3 per cent of the original medicine&#039;s price on the grounds that Bayer&#039;s drug was not meeting public health requirement.&lt;br /&gt;&lt;br /&gt;A month&#039;s dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer&#039;s appeal with the intellectual property appellate board is pending.&lt;br /&gt;&lt;br /&gt;Multinational companies as well as some countries, including the US, have been critical about India&#039;s implementation of IP laws and the liberal use of the compulsory licence provision.&lt;br /&gt;&lt;br /&gt;However, MNCs disagree that India could have been a trigger for China&#039;s move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &amp;quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country&#039;s requirement.&amp;quot;&lt;br /&gt;&lt;br /&gt;India and China, which together account for about a third of the world&#039;s population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.&lt;br /&gt;&lt;br /&gt;&amp;quot;If two or three big countries take similar steps, others will follow,&amp;quot; Shah said.&lt;br /&gt;&lt;br /&gt;Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp;amp; Singh, said India&#039;s IP laws strike a balance between protecting innovation and safeguarding public health. &amp;quot;Developing countries are now following our model,&amp;quot; she said.&lt;br /&gt;&lt;br /&gt;New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.&lt;br /&gt;&lt;br /&gt;In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.&lt;br /&gt;&lt;br /&gt;&amp;quot;The benefits of incorporating the provisions are apparent to many countries,&amp;quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &amp;quot;blindly adopt US and EU patent laws&amp;quot;. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh | Im4change.org</title>
    <meta name="description" content="
-The Economic Times

A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Economic Times<br /><br />A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br /><br />Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br /><br />Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br /><br />Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br /><br />According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br /><br />In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br /><br />A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br /><br />Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br /><br />However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br /><br />India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br /><br />&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br /><br />Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br /><br />New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br /><br />In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br /><br />&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 15697,
		'title' => 'More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh',
		'subheading' => '',
		'description' => '<div align="justify">
-The Economic Times<br />
<br />
A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br />
<br />
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br />
<br />
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br />
<br />
Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br />
<br />
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br />
<br />
In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br />
<br />
A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br />
<br />
Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br />
<br />
However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br />
<br />
India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br />
<br />
&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br />
<br />
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br />
<br />
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br />
<br />
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br />
<br />
&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br />
</div>',
		'credit_writer' => 'The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 15824,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 15697,
	'metaTitle' => 'LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh',
	'metaKeywords' => 'patents,medicines,Health',
	'metaDesc' => '
-The Economic Times

A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...',
	'disp' => '<div align="justify">-The Economic Times<br /><br />A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br /><br />Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br /><br />Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br /><br />Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br /><br />According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br /><br />In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br /><br />A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br /><br />Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br /><br />However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br /><br />India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br /><br />&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br /><br />Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br /><br />New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br /><br />In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br /><br />&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 15697,
	'title' => 'More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh',
	'subheading' => '',
	'description' => '<div align="justify">
-The Economic Times<br />
<br />
A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br />
<br />
Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br />
<br />
Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br />
<br />
Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br />
<br />
According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br />
<br />
In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br />
<br />
A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br />
<br />
Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br />
<br />
However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br />
<br />
India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br />
<br />
&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br />
<br />
Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br />
<br />
New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br />
<br />
In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br />
<br />
&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br />
</div>',
	'credit_writer' => 'The Economic Times, 22 June, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/more-nations-adopting-indian-intellectual-property-regulations-for-drug-',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'more-nations-adopting-indian-intellectual-property-regulations-for-drug-manufacturing-khomba-singh-15824',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 15824,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 15697
$metaTitle = 'LATEST NEWS UPDATES | More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh'
$metaKeywords = 'patents,medicines,Health'
$metaDesc = '
-The Economic Times

A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.

Although multinational companies have criticised India for being lax in...'
$disp = '<div align="justify">-The Economic Times<br /><br />A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health.<br /><br />Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions.<br /><br />Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies.<br /><br />Experts say IP laws were earlier framed in the West and adopted by developing countries. &quot;Strangely, India is now setting the IP laws for developing countries,&quot; said Shamnad Basheer, a Kolkata-based professor of IP Law.<br /><br />According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. &quot;It was a question of who will bell the cat,&quot; Shah said.<br /><br />In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement.<br /><br />A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending.<br /><br />Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision.<br /><br />However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, &quot;Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement.&quot;<br /><br />India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries.<br /><br />&quot;If two or three big countries take similar steps, others will follow,&quot; Shah said.<br /><br />Prathiba M Singh, managing attorney at Delhi-based law firm Singh &amp; Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. &quot;Developing countries are now following our model,&quot; she said.<br /><br />New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis.<br /><br />In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one.<br /><br />&quot;The benefits of incorporating the provisions are apparent to many countries,&quot; said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not &quot;blindly adopt US and EU patent laws&quot;. <br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh

-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions of patented drugs under certain conditions, including meeting public health needs. Multinational drug makers say the use of the provision should be limited to national emergencies. Experts say IP laws were earlier framed in the West and adopted by developing countries. "Strangely, India is now setting the IP laws for developing countries," said Shamnad Basheer, a Kolkata-based professor of IP Law. According to DG Shah, secretary-general of Indian Pharmaceutical Alliance, while the move to amend IP laws in China had been underway for some years, the trigger was provided earlier this year by India's decision to grant compulsory licence to Natco Pharma. "It was a question of who will bell the cat," Shah said. In March, India issued the country's first compulsory licence, allowing Natco to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 per cent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement. A month's dosage of Nexavar costs Rs 2.8 lakh, making it unaffordable for the poor. Bayer's appeal with the intellectual property appellate board is pending. Multinational companies as well as some countries, including the US, have been critical about India's implementation of IP laws and the liberal use of the compulsory licence provision. However, MNCs disagree that India could have been a trigger for China's move. Tapan Ray, director-general of OPPI, the representative body of global drugmakers in India, said, "Amendment of a law is the prerogative of the country concerned, and it is specific to the country's requirement." India and China, which together account for about a third of the world's population, form a critical market for MNCs. IP laws favourable to MNCs enable them to increase sales in developing countries. "If two or three big countries take similar steps, others will follow," Shah said. Prathiba M Singh, managing attorney at Delhi-based law firm Singh & Singh, said India's IP laws strike a balance between protecting innovation and safeguarding public health. "Developing countries are now following our model," she said. New Delhi ushered in a new patent regime in 2005, allowing patent holders 20 years exclusive marketing rights. But the government also put in certain safeguards, such as Section 3(D), which prevents patent on incremental innovations of known compounds unless they provide enhanced therapeutic efficacy. This controversial stipulation was unsuccessfully challenged by Swiss drugmaker Novartis. In May this year, Argentina announced new guidelines for patents, which among others, listed strict conditions similar to the ones provided in Section 3(D) of Indian IP laws. Thailand, too, is pushing a similar clause, while the Philippines has already adopted one. "The benefits of incorporating the provisions are apparent to many countries," said Leena Menghaney, campaign co-ordinator (India) at Medecins Sans Frontieres, a health group that has been coordinating campaigns globally to ensure that developing countries do not "blindly adopt US and EU patent laws".